P.M. BRIEFING : Rorer, P&G; Plan Joint Venture
- Share via
FT. WASHINGTON, Pa. — Rorer Group Inc. today announced an alliance with Procter & Gamble Co. to develop and market prescription and over-the-counter pharmaceutical products.
The move comes one day after the suburban Philadelphia-based company announced a $1.7-billion agreement to merge operations with the pharmaceuticals operations of Rhone-Poulenc of Paris.
Under the terms of today’s joint venture, Procter & Gamble will obtain exclusive U.S. marketing and distribution rights to Rorer’s line of over-the-counter pharmaceuticals such as Maalox, Ascriptin and Perdiem.
Rorer, which will continue to manufacture the drugs, will gain rights to develop and market De-Nol, an anti-ulcer drug, and other prescription gastrointestinal compounds that Procter & Gamble has been developing.
Rorer will retain ownership of its brands, while Procter & Gamble will receive royalty payments for the prescription products. Both companies will share in the growth of the business.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
